Literature DB >> 11216203

Causes of Alzheimer's disease.

D G Munoz1, H Feldman.   

Abstract

It is now understood that genetic factors play a crucial role in the risk of developing Alzheimer's disease (AD). Rare mutations in at least 3 genes are responsible for early-onset familial AD. A common polymorphism in the apolipoprotein E gene is the major determinant of risk in families with late-onset AD, as well as in the general population. Advanced age, however, remains the major established risk factor for AD, although environmental variables may also have some role in disease expression. Some pathogenic factors directly associated with aging include oxidative damage and mutations in messenger RNA. Other factors unrelated to the aging process may, in the future, be amenable to therapeutic intervention by way of estrogen replacement therapy for postmenopausal women, anti-inflammatory drug therapy and reducing vascular risk factors. Older theories, such as aluminum playing a role in the pathogenesis of AD, have been mostly discarded as our understanding of pathogenic mechanisms of AD has advanced.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11216203      PMCID: PMC1232234     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  83 in total

1.  Amyloid beta protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance of A beta 42(43) and association of A beta 40 with cored plaques.

Authors:  H Fukumoto; A Asami-Odaka; N Suzuki; H Shimada; Y Ihara; T Iwatsubo
Journal:  Am J Pathol       Date:  1996-01       Impact factor: 4.307

2.  Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs.

Authors:  J C Breitner; K A Welsh; M J Helms; P C Gaskell; B A Gau; A D Roses; M A Pericak-Vance; A M Saunders
Journal:  Neurobiol Aging       Date:  1995 Jul-Aug       Impact factor: 4.673

3.  Qualitative and quantitative differences in senile plaque dystrophic neurites of Alzheimer's disease and normal aged brain.

Authors:  D Wang; D G Munoz
Journal:  J Neuropathol Exp Neurol       Date:  1995-07       Impact factor: 3.685

4.  Bone aluminium content in Alzheimer's disease.

Authors:  D O'Mahony; J Denton; J Templar; M O'Hara; J P Day; S Murphy; J B Walsh; D Coakley
Journal:  Dementia       Date:  1995 Mar-Apr

5.  Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study.

Authors:  D A Snowdon; S J Kemper; J A Mortimer; L H Greiner; D R Wekstein; W R Markesbery
Journal:  JAMA       Date:  1996-02-21       Impact factor: 56.272

6.  The effect of education on the incidence of dementia and Alzheimer's disease in the Framingham Study.

Authors:  J L Cobb; P A Wolf; R Au; R White; R B D'Agostino
Journal:  Neurology       Date:  1995-09       Impact factor: 9.910

7.  A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele.

Authors:  H Soininen; O Kosunen; S Helisalmi; A Mannermaa; L Paljärvi; S Talasniemi; M Ryynänen; P Riekkinen
Journal:  Neurosci Lett       Date:  1995-03-03       Impact factor: 3.046

8.  Risk factors in clinically diagnosed presenile dementia of the Alzheimer type: a case-control study in northern England.

Authors:  D P Forster; A J Newens; D W Kay; J A Edwardson
Journal:  J Epidemiol Community Health       Date:  1995-06       Impact factor: 3.710

9.  Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease.

Authors:  J Poirier; M C Delisle; R Quirion; I Aubert; M Farlow; D Lahiri; S Hui; P Bertrand; J Nalbantoglu; B M Gilfix; S Gauthier
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

10.  Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease.

Authors:  J C Morris; M Storandt; D W McKeel; E H Rubin; J L Price; E A Grant; L Berg
Journal:  Neurology       Date:  1996-03       Impact factor: 9.910

View more
  24 in total

Review 1.  Indices of metabolic dysfunction and oxidative stress.

Authors:  Gemma Casadesus; Paula I Moreira; Akihiko Nunomura; Sandra L Siedlak; William Bligh-Glover; Elizabeth Balraj; Grace Petot; Mark A Smith; George Perry
Journal:  Neurochem Res       Date:  2007-03-07       Impact factor: 3.996

2.  2,4-Di-tert-butylphenol from sweet potato protects against oxidative stress in PC12 cells and in mice.

Authors:  Soo Jung Choi; Jae Kyeom Kim; Hye Kyung Kim; Keith Harris; Chang-Ju Kim; Gwi Gun Park; Cheung-Seog Park; Dong-Hoon Shin
Journal:  J Med Food       Date:  2013-09-28       Impact factor: 2.786

Review 3.  Nanomedicine in Central Nervous System (CNS) Disorders: A Present and Future Prospective.

Authors:  Shringika Soni; Rakesh Kumar Ruhela; Bikash Medhi
Journal:  Adv Pharm Bull       Date:  2016-09-25

4.  Ethanol extract of Scutellaria baicalensis Georgi prevents oxidative damage and neuroinflammation and memorial impairments in artificial senescense mice.

Authors:  Kukhuon Jeong; Yong-Cheol Shin; Sunju Park; Jeong-Su Park; Namil Kim; Jae-Young Um; Hoyeon Go; Seungho Sun; Sundong Lee; Wansu Park; Youkyung Choi; Yunkyung Song; Gyungjun Kim; Chanyong Jeon; Jonghyeong Park; Keysang Lee; Oksun Bang; Seong-Gyu Ko
Journal:  J Biomed Sci       Date:  2011-02-08       Impact factor: 8.410

Review 5.  Dietary lipids in the aetiology of Alzheimer's disease: implications for therapy.

Authors:  Janelle L Cooper
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 6.  The environment, epigenetics and amyloidogenesis.

Authors:  Jinfang Wu; Md Riyaz Basha; Nasser H Zawia
Journal:  J Mol Neurosci       Date:  2007-04-17       Impact factor: 3.444

7.  Dietary folate, vitamin B-12, vitamin B-6 and incident Alzheimer's disease: the cache county memory, health and aging study.

Authors:  C Nelson; H J Wengreen; R G Munger; C D Corcoran
Journal:  J Nutr Health Aging       Date:  2009-12       Impact factor: 4.075

8.  Variability in the diagnosis and management of patients with Alzheimer's disease and cerebrovascular disease: results from the GALATEA multicentre, observational study.

Authors:  Pedro Gil; José Luis Dobato Ayuso; José Manuel Marey; Manuel Antón; Carlos Guzmán Quilo
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

9.  Cellular polyamines promote amyloid-beta (Aβ) peptide fibrillation and modulate the aggregation pathways.

Authors:  Jinghui Luo; Chien-Hung Yu; Huixin Yu; Rok Borstnar; Shina C L Kamerlin; Astrid Gräslund; Jan Pieter Abrahams; Sebastian K T S Wärmländer
Journal:  ACS Chem Neurosci       Date:  2013-01-16       Impact factor: 4.418

10.  Antiamnesic effects of ethyl acetate fraction from chestnut (Castanea crenata var. dulcis) inner skin on Aβ(25-35)-induced cognitive deficits in mice.

Authors:  Hee-Rok Jeong; Yu Na Jo; Ji Hee Jeong; Dong Eun Jin; Byung Gi Song; Soo Jung Choi; Dong-Hoon Shin; Ho Jin Heo
Journal:  J Med Food       Date:  2012-11-07       Impact factor: 2.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.